Can insulin resistance and hyperglycemia drive fatty liver and ALT elevation?

Insulin resistance and chronic hyperglycemia are central metabolic features of MASLD and provide a coherent explanation for increased liver-fat production. The overall claim is well supported for steatosis and biologically plausible—but less directly established—for ALT elevation.

Clinical and metabolic evidence

• Insulin resistance increases hepatic glucose output, hyperglycemia, and compensatory hyperinsulinemia. Glucose activates ChREBP and insulin activates SREBP-1c, increasing hepatic de novo lipogenesis (DNL).
• Human tracer studies link higher 24-hour glucose and insulin concentrations with greater DNL in NAFLD. DNL supplies approximately 20–30% of hepatic triglyceride production and contributes more in type 2 diabetes.
• Since hepatic triglyceride accumulation defines steatosis, this provides strong mechanistic support that dysglycemia promotes fatty liver. Type 2 diabetes and cardiometabolic risk appropriately warrant active assessment for MASLD and fibrosis.

Oxidative-stress and injury mechanisms

• Increased lipid delivery and DNL can exceed mitochondrial oxidative capacity. Incomplete fatty-acid oxidation, electron leakage, reduced oxidative phosphorylation, and lower ATP generation promote reactive oxygen species and lipid peroxidation.
• Lipotoxic species—not triglyceride alone—are most relevant to injury. Free fatty acids, diacylglycerols, ceramides, and free cholesterol can induce mitochondrial and endoplasmic-reticulum stress, inflammation, apoptosis, and hepatocellular injury, which may release ALT.
• Oxidative stress can also impair fatty-acid oxidation and insulin signaling, creating a reinforcing cycle that can accelerate MASLD.

Clinical interpretation

• The link from insulin resistance to hepatic fat production and steatosis is strongly supported. Oxidative stress and subsequent ALT elevation are mechanistically credible but less directly isolated in human studies.
• ALT is nonspecific: normal values do not exclude MASLD, steatohepatitis, or advanced fibrosis. Fibrosis risk should not be inferred from ALT alone; multistep assessment using FIB-4 and, when indicated, elastography or other validated noninvasive testing is more informative.

Bottom line

• Insulin resistance and hyperglycemia can meaningfully drive hepatic fat accumulation and plausibly promote oxidative injury and ALT elevation, but ALT alone cannot establish the mechanism or determine liver-disease severity.